drugset / Trial / NCT02097329

Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food

NCT02097329

Phase 1 Completed 27 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelBasic science

Summary

To investigate the effect of acid reducing agents (an antacid and an H2-receptor antagonist and a proton pump inhibitor) on palbociclib bioavailability in the presence of food.

Timeline

Start
2014-04
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Famotidine Other / unclassified 20 mg Oral
Subject Maalox Unknown 30 ml Oral
Subject Palbociclib Small molecule 125 mg Oral
Subject Rabeprazole Small molecule 40 mg Oral

Indications

No indication recorded.